<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04337463</url>
  </required_header>
  <id_info>
    <org_study_id>ATG-008-HX-001</org_study_id>
    <nct_id>NCT04337463</nct_id>
  </id_info>
  <brief_title>ATG-008 Combined With Toripalimab in Advanced Solid Tumors</brief_title>
  <official_title>An Open, Dose-escalation and Expansion Study With a Dual TORC1/2 Inhibitor of ATG-008 Combined With PD-1 Antibody of Toripalimab in Advanced Solid Tumors and Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-arm study with dose-escalation and expansion phases to access
      ATG-008 combined with Toripalimab in patients with advanced solid tumors and hepatocellular
      carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">March 17, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 17, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD</measure>
    <time_frame>Within 21 days after dosing</time_frame>
    <description>Maximum Tolerated Dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RP2D</measure>
    <time_frame>Within 21 days after dosing</time_frame>
    <description>Recommended phase 2 dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>Through study completion (approximately 2 years)</time_frame>
    <description>Overall Response Rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1 - Day 15</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>Day 1 - Day 15</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>ATG-008 and Toripalimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Toripalimab will be combined with ATG-008.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG-008</intervention_name>
    <description>Tablet</description>
    <arm_group_label>ATG-008 and Toripalimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>ATG-008 and Toripalimab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Know and voluntarily sign informed consent.

          2. Age 18-70 years old (including 18 and 70 years old), weight ≥50 Kg.

          3. At least one measurable lesion according to the RECIST 1.1 evaluation criteria.

          4. ECOG performance status score is 0 or 1.

          5. Blood chemistry test results, meet the following results:

               1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 ×
                  normal upper limit (ULN)

               2. Total bilirubin ≤ 1.5 × ULN

               3. Serum albumin&gt; 29 g / L

               4. Creatinine ≤ 1.5 × ULN or 24-hour serum creatinine clearance ≥ 50 mL / min

               5. Lipase and amylase ≤ 2 × ULN.

          6. Adequate bone marrow function and meets the following results:

               1. Absolute neutrophil count (ANC) ≥ 1.5 × 109 / L

               2. Platelets ≥ 75 × 109 / L

               3. Hemoglobin ≥ 90 g / L.

          7. Coagulation function: International Normalized Ratio (INR) ≤ 2.0, Prothrombin Time
             (PT) ≤ 1.5 × ULN.

          8. Subjects with hepatitis B virus (HBV) infection (hepatitis B surface antigen [HBsAg]
             positive) must undergo antiviral therapy during the study period, and the HBV-DNA
             should be ≤500 IU / mL before enrollment.

          9. Except for hearing loss and hair loss, all toxicity caused by previous anti-tumor
             therapy must have returned to ≤ Grade 1 (according to NCI-CTCAE version 5.0).

         10. Life expectancy is longer than 3 months.

         11. Fertile men and women in childbearing age must agree to use effective contraceptives
             from the period they sign the informed consent until 180 days after the last study
             drug. Women of childbearing age include premenopausal women and women within 2 years
             after menopause. Women in childbearing age must have a negative blood pregnancy test
             within 3 days of the first study drug.

        Inclusion criteria only met in dose escalation phase：

        1. Subjects are histopathologically diagnosed with advanced, relapsed or refractory solid
        tumors (including but not limited to breast cancer, neuroendocrine cancer, lung cancer,
        bile duct cancer, adenocarcinoma of gastroesophageal junction and HCC. Subjects with HCC
        will meet the inclusion criteria of the dose expansion phase, without standard treatment
        available, and intolerance or rejection of standard treatment.

        Inclusion criteria only met in dose expansion phase： 1. Following the 2018 version of
        primary liver cancer diagnosis and treatment guidelines, pathologically or clinically
        confirmed HCC.

          1. Stage B (Mid-term) identified as unresectable or Stage C (Advanced) HCC according to
             Barcelona Clinical Liver Cancer Staging (BCLC). Subjects in stage B must have been
             progressed after surgery or local treatment, or be unsuitable for surgery or local
             treatment.

          2. Have previously received at least one type of systemic therapy for HCC (including
             sorafenib, oxaliplatin-based chemotherapy, lenvatinib, or regorafenib).

          3. Child-Pugh A or Child-Pugh B7 with a hepatic encephalopathy score of 1.

        Exclusion Criteria:

          1. Inability to tolerate sorafenib / regorafenib.

          2. Have a history of hepatic encephalopathy.

          3. Have central nervous system metastases.

          4. Have a thyroid disorder with a clinically significant thyroid dysfunction judged by
             the investigator.

          5. Active or history of upper gastrointestinal bleeding, ulcers, or esophageal varices
             with bleeding within 6 months.

          6. Simultaneous infection with HBV and hepatitis C virus (HCV).

          7. Major surgery has been performed within 4 weeks before the first dose, or is expected
             during the study period.

          8. Have received systemic chemotherapy, radiotherapy, Chinese medicine with antitumor
             activity, or local treatment for HCC (including but not limited to radiofrequency
             ablation, transcatheter arterial chemoembolization, and high-intensity focused
             ultrasound) within 4 weeks before the first dose.

          9. Previously received immunotherapy (including anti-PD-1, anti-PD-L1, CTLA-4 or CAR-T
             cell therapy), or received mTOR (TORC1 and / or TORC2) inhibitors and / or PI3K / AKT
             / MTOR inhibitors treated subjects.

         10. Received live attenuated vaccine within 4 weeks prior to first study dose (subjects
             should not receive live attenuated vaccine at the time of study drug administration
             and up to 28 days after the last dose if enrolled ).

         11. Have a history of organ transplantation (eg., liver transplantation).

         12. Poorly-controlled pleural or pericardial effusion (with clinical symptoms, fluctuating
             fluid or requiring repeated drainage, oral diuretics, etc.) during the screening
             period. Ascites can be detected during the physical examination during screening, or
             with clinical symptoms, or require special treatment, such as repeated drainage,
             intraperitoneal drug perfusion, etc. (But subjects could consider enrollment if the
             ascites were only found in the imageological examination).

         13. Other primary malignancies occurred within 5 years before the first administration of
             the study drug with the exception of locally curable malignancies

         14. Suffering from active or previously recurring autoimmune diseases or under such a
             risk.

         15. Systemically immunosuppressive drugs are currently used within 14 days of the first
             dose.

         16. ≥ Grade 2 diarrhea or malabsorption (NCI-CTCAE v5.0) persists after treatment, or any
             significant gastrointestinal disorder that may affect study drug absorption.

         17. Suffer a persistent or active infection, a history of pneumonia due to immunotherapy,
             or currently have Grade 2 above pneumonia. Or, a history of active tuberculosis
             infection within 1 year before the first dose was administered (subjects with a
             history of active tuberculosis infection more than 1 year ago, and they were deemed to
             be eligible if they had no evidence of active tuberculosis).

         18. Subjects with a history of human immunodeficiency virus (HIV) virus infection and / or
             acquired immunodeficiency syndrome.

         19. Have clinically significant cardiovascular diseases, such as Class II or above cardiac
             abnormalities (NYHA standard), ischemic heart disease (such as myocardial infarction
             or unstable angina pectoris), clinically significant supraventricular or ventricular
             arrhythmias, poorly controlled hypertension (systolic blood pressure&gt; 150 mmHg and /
             or diastolic blood pressure&gt; 100 mmHg), or echocardiogram showing ejection fraction
             &lt;50%, or QTc interval, male&gt; 450 msec, female&gt; 470 msec.

         20. Have a history of severe allergic reactions to chimeric, human or humanized
             antibodies, or fusion proteins; Known to have hypersensitivity reactions to any
             components to be produced for CHO cells, or a Toripalimab monoclonal antibody (such as
             citric acid monohydrate, sodium citrate dihydrate, mannitol, polysorbate).

         21. The investigator considers that the complications or other situations of the subject
             may affect compliance with the protocol, or are not suitable for participation in this
             study.

        Exclusion criteria only met in dose escalation phase

        1. Subjects with diabetes or glycated hemoglobin (HbA1c)&gt; 7%. Exclusion criteria only met
        in dose expansion phase：

          1. Histopathological diagnosis was fibrous lamellar HCC, sarcomatoid HCC, bile duct cell
             carcinoma, or mixed liver cancer.

          2. Have received molecular targeted therapy, such as sorafenib, or lenvatinib within 4
             weeks before the first dose.

          3. Have received palliative surgery in the liver area, local treatment of HCC (such as
             intervention, ablation, absolute alcohol injection, etc), or radiotherapy within 4
             weeks before the first dose.

          4. Imaging shows main portal vein, inferior vena cava tumor thrombus, or heart
             involvement.

          5. Poorly controlled diabetes (HbA1c&gt; 7%).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Zheng</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Zheng</last_name>
    <phone>+86 028-85423655</phone>
    <email>lzheng2005618@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zheng</last_name>
      <phone>+86 028-85423655</phone>
      <email>lzheng2005618@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 21, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2020</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan University</investigator_affiliation>
    <investigator_full_name>Li Zheng</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

